Document:

EX-10.1

 Exhibit 10.1 

Idera Pharmaceuticals, Inc. 

Nonstatutory Stock Option Agreement 
 1. Grant
of Option. 
 This agreement evidences the grant by Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), on
[            ] (the “Grant Date”) to [            ], an employee of the Company (the “Participant”), of an
option to purchase, in whole or in part, on the terms provided herein, a total of [            ] shares (the “Shares”) of common stock, $0.001 par value per share, of the Company
(“Common Stock”) at $[        ] per Share. Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on
[            ] (the “Final Exercise Date”). 
 The option evidenced by
this agreement was granted to the Participant pursuant to the inducement grant exception under NASDAQ Stock Market Rule 5635(c)(4), and not pursuant to the Company’s 2013 Stock Incentive Plan (the “Plan”) or any equity incentive plan
of the Company, as an inducement that is material to the Participant’s employment with the Company. 
 It is intended that the option
evidenced by this agreement shall not be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). Except as otherwise indicated by
the context, the term “Participant”, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms. 

2. Vesting Schedule. 
 This option will
become exercisable (“vest”) as follows: [            ]. 
 The right
of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the
earlier of the Final Exercise Date or the termination of this option. 
 3. Exercise of Option. 

(a) Form of Exercise. Each election to exercise this option shall be in writing, signed by the Participant, and received by the Company
at its principal office, accompanied by this agreement and payment in full as follows: 
 (1) in cash, by check or by wire transfer, payable
to the order of the Company; 
 (2) by (i) delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver
promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker to deliver
promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; 

 (3) to the extent approved by the Board of Directors of the Company (the “Board”), in
its sole discretion, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their fair market value per share as determined by (or in a manner approved by) the Board (the “Fair Market
Value”), provided (i) such method of payment is then permitted under applicable law, (ii) such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be
established by the Board in its discretion and (iii) such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements; 

(4) to the extent approved by the Board, in its sole discretion, by delivery of a notice of “net exercise” to the Company, as a
result of which the Participant would receive (i) the number of shares underlying the portion of this being exercised, less (ii) such number of shares as is equal to (A) the aggregate exercise price for the portion of this option
being exercised divided by (B) the Fair Market Value on the date of exercise; 
 (5) to the extent permitted by applicable law and
approved by the Board, in its sole discretion, by payment of such other lawful consideration as the Board may determine; or 
 (6) by any
combination of the above permitted forms of payment. 
 The Participant may purchase less than the number of shares covered hereby, provided that no partial
exercise of this option may be for any fractional share or for fewer than ten whole shares. 
 (b) Continuous Relationship with the
Company Required. Except as otherwise provided in this Section 3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, officer
or a director of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an “Eligible Participant”). 

(c) Termination of Relationship with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except
as provided in paragraphs (d), (e) and (f) below, the right to exercise this option shall terminate three months after such cessation (but in no event after the Final Exercise Date), provided that this option shall be
exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or
confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon written notice to the
Participant from the Company describing such violation. 
 (d) Exercise Period Upon Death or Disability. If the Participant dies or
becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship for “cause” as specified in
paragraph (e) below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), provided
that this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final
Exercise Date. 

  
 2 

 (e) Termination for Cause. If, prior to the Final Exercise Date, the Participant’s
employment or other relationship with the Company is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment or other
relationship. If the Participant is party to an employment, consulting or severance agreement with the Company that contains a definition of “cause” for termination of employment or other relationship, “Cause” shall have the
meaning ascribed to such term in such agreement. Otherwise, “Cause” shall mean willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without
limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the Company), as determined by the Company, which determination
shall be conclusive. The Participant shall be considered to have been discharged for “Cause” if the Company determines, within 30 days after the Participant’s resignation, that discharge for cause was warranted. 

4. Transfer Restrictions. This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or
by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant. 

5. Adjustments for Changes in Common Stock and Certain Other Events. 

(a) Changes in Capitalization. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of
shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, the number and class of securities and exercise price
per share of this option shall be equitably adjusted by the Company (or substituted options may be granted, if applicable) in the manner determined by the Board. Without limiting the generality of the foregoing, in the event the Company effects a
split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to this option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend),
then the Participant, if he exercises this option between the record date and the distribution date for such stock dividend, shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock
acquired upon exercise of this option, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend. 

(b) Reorganization Events. 

(1) Definition. A “Reorganization Event” shall mean: (a) any merger or consolidation of the Company with or into another
entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b) any transfer or disposition of all of the Common Stock of the
Company for cash, securities or other property pursuant to a share exchange or other transaction or (c) any liquidation or dissolution of the Company. 

  
 3 

 (2) Consequences of a Reorganization Event on Awards Other than Restricted Stock. 

(A) In connection with a Reorganization Event, the Board may take any one or more of the following actions with respect to this option (or any
portion thereof) on such terms as the Board determines (except to the extent specifically provided otherwise in another agreement between the Company and the Participant): (i) provide that this option shall be assumed, or substantially
equivalent option shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to the Participant, provide that the unexercised portion of this option will terminate immediately prior to
the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable) within a specified period following the date of such notice, (iii) provide that this option shall become exercisable in whole or
in part prior to or upon such Reorganization Event, (iv) in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the
Reorganization Event (the “Acquisition Price”), make or provide for a cash payment to the Participant with respect to this option equal to (A) the number of shares of Common Stock subject to the vested portion of this option (after
giving effect to any acceleration of vesting that occurs upon or immediately prior to such Reorganization Event) multiplied by (B) the excess, if any, of (I) the Acquisition Price over (II) the exercise price of this option and any
applicable tax withholdings, in exchange for the termination of this option, (v) provide that, in connection with a liquidation or dissolution of the Company, this option shall convert into the right to receive liquidation proceeds (if
applicable, net of the exercise price thereof and any applicable tax withholdings) and (vi) any combination of the foregoing. 
 (B)
For purposes of Section 5(b)(2)(A)(i), this option shall be considered assumed if, following consummation of the Reorganization Event, this option confers the right to purchase, for each share of Common Stock subject to this option immediately
prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior
to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the
consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for
the consideration to be received upon the exercise of this option to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determined to be equivalent in value (as
of the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event. 

  
 4 

 6. Miscellaneous. 

(a) No Right To Employment or Other Status. The grant of this option shall not be construed as giving the Participant the right to
continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with the Participant free from any liability or claim hereunder. 

(b) No Rights As Stockholder. Subject to the provisions of this option, the Participant shall not have any rights as a stockholder with
respect to any shares of Common Stock to be distributed with respect to this option until becoming the record holder of such shares. 
 (c)
Amendment. The Board may amend, modify or terminate this Agreement, including but not limited to, substituting another option of the same or a different type and changing the date of exercise or realization. Notwithstanding the foregoing, the
Participant’s consent to such action shall be required unless the Board determines that the action, taking into account any related action, would not materially and adversely affect the Participant. 

(d) Compliance with Code Section 409A. This Agreement does not, and shall not be amended so as to, provide for deferral of
compensation that does not comply with Section 409A of the Code, unless the Board, at the time of amendment, specifically provides that this Agreement is not intended to comply with Section 409A of the Code. 

(e) Acceleration. The Board may at any time provide that this option shall become immediately exercisable in whole or in part, free of
some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. 
 (f) Withholding. The
Participant must satisfy all applicable federal, state, and local or other income and employment tax withholding obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under this option. The
Company may decide to satisfy the withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any,
required for withholding or have a broker tender to the Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any shares on exercise of this option or at the same time as payment
of the exercise price, unless the Company determines otherwise. If approved by the Board, in its sole discretion, a Participant may satisfy such tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of
Common Stock underlying this option valued at their Fair Market Value; provided, however, except as otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the
Company’s minimum statutory withholding obligations (based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income). Shares used to satisfy tax
withholding requirements cannot be subject to any forfeiture, unfulfilled vesting or other similar requirements. 
 (g) Conditions on
Delivery of Stock. The Company will not be obligated to deliver any shares of Common Stock pursuant to this Agreement until (i) all conditions of this 

  
 5 

 
Agreement have been met to the satisfaction of the Company, (ii) in the opinion of the Company’s counsel, all other legal matters in connection with the issuance and delivery of such
shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such
representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. 

(h) Administration by Board. The Board will administer this Agreement and may construe and interpret the terms hereof. The Board may
correct any defect, supply any omission or reconcile any inconsistency in this Agreement in the manner and to the extent it shall deem expedient to carry the Agreement into effect and it shall be the sole and final judge of such expediency. No
director or person acting pursuant to the authority delegated by the Board shall be liable for any action or determination relating to or under this Agreement made in good faith. 

(i) Appointment of Committees. To the extent permitted by applicable law, the Board may delegate any or all of its powers hereunder to
one or more committees or subcommittees of the Board (a “Committee”). All references herein to the “Board” shall mean the Board or a Committee to the extent that the Board’s powers or authority hereunder have been delegated
to such Committee. 
 (j) Severability. The invalidity or unenforceability of any provision hereof shall not affect the validity or
enforceability of any other provision hereof, and each such other provision shall be severable and enforceable to the extent permitted by law. 

(k) Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding
choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than the State of Delaware. 

(l) Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of
which together will constitute one in the same instrument. 
 The Company has caused this option to be executed by its duly authorized
officer. 
  

			
	IDERA PHARMACEUTICALS, INC.
		
	By:	 	 
	Name:	 	
	Title:	 	

  
 6 

 PARTICIPANT’S ACCEPTANCE 

The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. 

 

	
	PARTICIPANT
	
	   

	Name:
	
	Address:
	
	Telephone:

  
 7Exhibit

Exhibit 10.3

THIS OFFER LETTER SUPERSEDES ANY PREVIOUS WRITTEN OR VERBAL OFFER LETTER EXTENDED TO YOU PRIOR TO THE DATE OF THIS LETTER.

August 11, 2015

Peter Kuipers

Dear Peter, 

We are pleased to offer you the position of Executive Vice President, Chief Financial Officer, reporting to Randall Lipps.  Your bi-weekly salary will be $14,230.77, less payroll deductions and all required withholdings, which is an annual equivalent of $370,000.00.  Omnicell will recommend, for approval by our Board of Directors, an award to you of options to purchase up to 37,500 shares of Omnicell Common Stock at a price equal to the fair market value of such shares on the date of grant.  Upon approval those shares will become exercisable over a four year vesting period, with a one-year cliff.  The options will be subject to the terms and conditions of Omnicell’s stock option plan and your grant agreement. In addition, Omnicell will recommend an award of 22,500 shares of restricted stock units (RSUs) which will vest in equal increments every 6 months on June 15 and December 15 over a four year vesting period.

Your target start date for employment is August 24, 2015.  Please notify us immediately if that changes.
You will be eligible to participate in the Omnicell 2010 Quarterly Executive Bonus Plan wherein you may receive a bonus in the amount of up to 50% of the base salary paid to you during the quarter, pending Board approval and paid out pursuant to such Bonus Plan terms; provided, among other things, the company's and your personal objectives are met. Please note that participation in the Executive Bonus Plan is at the discretion of Omnicell's Board of Directors and that they reserve the right to make changes to such bonus plan at any time. As a new hire, you are eligible to participate in this bonus program in the first quarter where you are employed as of the 15th calendar day of the 2nd month of the calendar quarter and have approved goals established with the Board of Directors. 
You may also be eligible to participate, on a pro-rata basis, in the 2015 Over Achievement Bookings Bonus, to be evaluated based on overachievement of company bookings. Any bonuses are earned and paid at the discretion of the Omnicell Board of Directors. 

Omnicell provides an annual executive perquisite allowance of $6,000 which is paid out on a quarterly basis. The quarterly amount may be prorated based on the start date within the quarter.  This allowance may be used in your discretion for financial planning fees, health club memberships, or any other appropriate perquisite, and will not be grossed up for tax purposes.  Perquisites expenses over and above the allowance will only be reimbursed on an exceptional basis at the discretion of Omnicell.
As an executive officer at Omnicell you are also eligible for change of control benefits set forth in our executive Change of Control Agreement, and are eligible to receive executive officer indemnity protection under our Indemnity Agreement provided separately.
If your employment is terminated without cause you will be eligible to receive severance pay in accordance with Omnicell's then current and published Omnicell’s Amended and Restated Severance Benefit Plan provided you agree to abide by the terms of such plan, including but not limited to agreeing to execute Omnicell's standard waiver and release agreement. Under the current plan your position is offered the equivalent to twelve (12) months' salary at your base rate of pay in effect immediately prior to termination. 

As an exempt executive and Chief Financial Officer you will not accrue vacation under the accrued vacation policy that Omnicell offers to certain other employment positions.  Instead, you will be eligible to take reasonable time off with pay under the Company’s non-accrual vacation policy.  Generally, you will have no set guideline as to how much time off you will be permitted to take; however, “unused” vacation time will not be carried over from one year to the next, nor will any vacation time be paid out upon termination.  You will receive a written policy with detailed information on this program, which the Company believes is the best approach to allow you to take time off yet adequately cover your responsibilities.  

Employment at Omnicell is at-will employment, which means it may be terminated by you or by Omnicell at any time without liability, and is acknowledged by you upon signing this offer letter.  In addition, Omnicell may change your position, duties, compensation, benefits and work location from time to time at its discretion.  

This offer is contingent upon successful completion of background and reference checks, and drug screen even where a start date of employment has been determined.  Certain positions include a credit check as part of the background check. Please keep in mind the contingent nature of this offer when making any decisions regarding the timing of any notice of termination of any employment and/or other relationship, as applicable. 

We have competitive medical, dental and vision plans as well as term life, long and short term disability insurance policies, and 401(k) plan.  Details about these benefits are provided in the Employee Handbook and Summary Plan Descriptions, available for your review.  Omnicell may, however, change compensation and benefits from time to time at its discretion.

As a condition of employment and required by law, you must show proof of citizenship, permanent residency in the United States or authorization to work in the United States.  To complete the federally-required verification form (I-9), we ask that you submit copies of this documentation with your new hire materials during your first week of employment.  Documents may include a US Passport, birth certificate, Social Security Card, driver’s license or Alien Registration Receipt Card.  

As an Omnicell employee, you will be expected to abide by company policies and procedures, and acknowledge in writing that you have read and will comply with the company’s Employee Handbook.  As a condition of employment, you must read, sign and comply with the attached Proprietary Information Agreement which prohibits unauthorized use or disclosure of Company proprietary information.  In addition as part of your duties for Omnicell, you may be assigned to work onsite with an Omnicell customer or otherwise to provide services to or interact with an Omnicell customer.  Some of these customers have additional requirements that they impose upon individuals who work onsite at their facility or have access to their patient health information, including, but not limited to, the requirement that you submit to drug-testing, testing for various infectious diseases and/or additional background/screening checks.  If you are assigned to work with such a customer, you will be given notice of the customer’s additional requirements and will be required to fulfill these requirements as a condition of your employment with Omnicell. 

If you have any questions, please give Wendi Ellis a call at (615) 564-7183.  Please note the above offer is good for five (5) days from the date of issue.

On behalf of Randall Lipps, I am pleased to confirm your offer to join Omnicell.  We are looking forward to having you on our team!

We look forward to working with you in this exciting stage of our company’s development.  We believe you will make a significant contribution to the company and the opportunities available to you will be wide open as Omnicell grows to its potential.

Sincerely,

/s/ Wendi Ellis 

Wendi Ellis

Director, Staffing
Be the Solution. Imagine the Impact.

To indicate your acceptance of the company’s offer, please sign and date this letter in the space provided below and return it to Staffing via confidential fax at 877-285-3149.  You may keep the original copy of this letter. This letter, along with the Proprietary Information Agreement, Policy Against Trading on the Basis of Inside Information and the Code of Ethics between you and the Company, Omnicell, set forth the terms of your employment with Omnicell and supersede any prior representations or agreements, whether written or oral.  The above listed documents will be sent electronically through our onboarding system for your review. Should you want hard copies prior to signing your offer letter please let us know. This letter may not be modified or amended except by a written agreement, signed by Omnicell and by you.  The above offer is good for five (5) days from the date of issue.

_____/s/ Peter Kuiper_______________________        ___8/12/15______________
Candidate Signature                        Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]